About celldex therapeutics - CLDX
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
CLDX At a Glance
Celldex Therapeutics, Inc.
Perryville III Building
Hampton, New Jersey 08827
| Phone | 1-908-454-7120 | Revenue | 1.55M | |
| Industry | Biotechnology | Net Income | -258,757,000.00 | |
| Sector | Health Technology | Employees | 198 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CLDX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1,167.651 |
| Price to Book Ratio | 3.429 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.55 |
| Enterprise Value to Sales | 836.365 |
| Total Debt to Enterprise Value | 0.002 |
CLDX Efficiency
| Revenue/Employee | 7,803.03 |
| Income Per Employee | -1,306,853.535 |
| Receivables Turnover | 0.241 |
| Total Asset Turnover | 0.002 |
CLDX Liquidity
| Current Ratio | 10.485 |
| Quick Ratio | 10.485 |
| Cash Ratio | 10.084 |
CLDX Profitability
| Gross Margin | -118.77 |
| Operating Margin | -18,599.806 |
| Pretax Margin | -16,748.026 |
| Net Margin | -16,748.026 |
| Return on Assets | -37.629 |
| Return on Equity | -40.616 |
| Return on Total Capital | -48.868 |
| Return on Invested Capital | -40.516 |
CLDX Capital Structure
| Total Debt to Total Equity | 0.443 |
| Total Debt to Total Capital | 0.441 |
| Total Debt to Total Assets | 0.401 |
| Long-Term Debt to Equity | 0.149 |
| Long-Term Debt to Total Capital | 0.148 |